search
Back to results

Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.

Primary Purpose

Active Non Segmental Vitiligo

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Narrow band ultraviolet B
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Active Non Segmental Vitiligo

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Age: ≥ 18 years.
  • Both genders.
  • Type of Vitiligo: non segmental vitiligo (NSV).
  • Active disease for less than 6 months (VIDA ≥ +2).
  • No systemic or topical treatment for vitiligo for at least one month.

Exclusion criteria:

  • Patients less than 18 years.
  • VIDA ≤ +1.
  • Contraindications to phototherapy (precancerous conditions like
  • Xeroderma pigmentosum , photosensitivity, history of arsenic intake,
  • ionizing radiation, extensive previous exposure to PUVA, patients
  • with a history of melanoma, atypical nevi, non-melanoma skin
  • cancers and patients taking immunosuppressive medications ( Menter et al., 2010 and Mehta & Lim, 2016).
  • Pregnancy and lactation .
  • Patients who received systemic or topical treatment for the past
  • month.
  • patients having any autoimmune diseases .

Sites / Locations

  • Nourhan Emad

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Active vitiligo patients

Arm Description

NBUVB

Outcomes

Primary Outcome Measures

Effect of NB-UVB on tissue level of IL 15 and IL15Rα in active vitiligo
Change of tissue level of Il-15 and IL-15Rα after 48 session of NB-UVB

Secondary Outcome Measures

Effect of activity of vitiligo on tissue level of Il-15 and IL-15Rα
Correlation between tissue level of Il-15 and IL-15Rα before and after NB-UVB with activity score (vitiligo digns of activity score from 0 to 15)
Effect of extent of vitiligo on tissue level of Il-15 and IL-15Rα
Correlation between tissue level of Il-15 and IL-15Rα before and after NB-UVB with extent score (Vitiligo extent plus score )

Full Information

First Posted
February 18, 2022
Last Updated
August 8, 2022
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT05316987
Brief Title
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
Official Title
Effect of Narrow Band Ultraviolet B on the Tissue Level of Interleukin 15 and Interleukin 15 Receptor Alpha Subunit in Active Non Segmental Vitiligo Cases.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
April 30, 2022 (Actual)
Primary Completion Date
July 30, 2022 (Actual)
Study Completion Date
July 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims at evaluating the effect of NB-UVB on tissue level of IL-15 and IL-15 receptor alpha subunit (IL-15Rα)(CD215) in active non segmental vitiligo. This in turn will shed light on the potential role of phototherapy as a safe mean of prevention of vitiligo recurrence as well as evaluating the utility of IL 15 and IL 15 Rα as markers of vitiligo activity/recurrence.
Detailed Description
Vitiligo is a T cell-mediated, autoimmune cutaneous disorder characterized by loss of functioning melanocytes from the basal layer of epidermis and/or hair follicles, leading to depigmented areas of the skin, mucous membranes, and/or hair (Strassner et al., 2018). Multiple factors have been involved in disease development, with a prominent role of the immune system, in particular T cells. After repigmentation, vitiligo usually recurs in the same area, drawing attention to the fact that resident memory T cells (TRM) are present at the sites of vitiligo lesions. This was confirmed by a number of studies (Boniface et al., 2018 , Boniface& Seneschal., 2019 , Riding& Harris., 2019) showing that stable and active vitiligo perilesional skin is enriched with a population of CD8 TRM expressing both CD69 and CD103. CD8 TRM expressing CD103 are localized mainly in the epidermis. IL-15 is the only identified cytokine required for maintenance of CD8 TRM cells (Baumann et al., 2018 and Richmond et al., 2018). Interleukin 15(IL-15) is one of Interleukin 2(IL-2) family members. It plays an important function in the pathogenesis of multiple cutaneous autoimmune diseases as psoriasis (Rückert et al.,2000) , alopecia areata (Ebrahim et al.,2019) and vitiligo (Atwa et al.,2020). IL-15 receptor (IL-15R) is expressed on natural killer cells, dendritic cells, monocytes, fibroblasts, T cells and keratinocytes . IL-15R is composed of α (CD215), β (CD122), and γ (CD132) chains , The alpha chain occurs as both a soluble and a membrane-attached subunit (Vámosi et al., 2004 , Budagian et al., 2006 and Di Sabatino et al.,2011). IL-15 stimulates neighbor cells by a trans-presentation mechanism through secretion of (IL-15. IL-15Rα complexes) from the surface of monocytes or dendritic cells into endosomes for its presentation in trans to neighboring cytotoxic cells or Natural killer cells ( Stonier & Schluns .,2010). IL-15 enhances maturation and survival of natural killer (NK) cells, neutrophils, and Dendritic cells (DCS) (Di Sabatino et al.,2011). Additionally, IL-15 promotes NK cell cytotoxicity and cytokine production such as interferon gamma( IFN-γ )and tumour necrosis factor alfa (TNF-α) (Fehniger & Caligiuri .,2001). As for DCs, they regulate the development and survival of memory cytotoxic cells by IL-15 trans-presentation ( Budagian et al., 2006 and Stonier & Schluns.,2010). Furthermore, IL-15 promotes T-cell receptor-dependent proliferation of Th17 (Di Sabatino et al.,2011). TRM primarily express the CD122 (IL-15R β) subunit, a shared component of the receptors for IL-2 and IL-15, whereas keratinocytes express more CD215(IL-15Rα) in lesional compared to non lesional skin which is consistent with an ability to present IL-15 to T cells in trans (Richmond et al., 2018). CD122(IL-15R β) expression is significantly higher on melanocyte-specific T cells in both mouse and human vitiligo compared to endogenous memory T cells, suggesting that autoreactive T cells are more dependent on IL-15 than non-autoreactive T cells. In addition, anti-CD122 blocking antibody inhibit IL-15 mediated T cell survival but not IL-2-mediated proliferation in vitro. This is consistent with the role of IL-15 in mediating T cell survival, but not proliferation (Riding et al., 2018). These findings are consistent with an important role of IL-15 in maintenance of autoreactive TRM cells in vitiligo and suggest that this could be an effective targeted treatment strategy for vitiligo patients ( Frisoli et al., 2020). Phototherapy has been considered as a cornerstone in management of vitiligo patients (Esmat et al., 2017). Narrow band ultraviolet B (NB-UVB) has been found to be an effective and well-tolerated treatment option in vitiligo compared to other available photo(chemo)therapy options (Sokolova et al., 2015). Regarding effect of Ultraviolet B treatment on IL-15 in normal skin, it was found to increase IL-15 expression in epidermal and dermal sheets as well as in cultured keratinocytes and dermal fibro-blasts (Mohamadzadeh et al.,1995). However, this was negated by Blauvet et al. in 1996 who proved that IL-15 expression is down regulated by UVB in cultured keratinocytes in a dose and time dependent manner (Blauvet et al., 1996).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Active Non Segmental Vitiligo

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active vitiligo patients
Arm Type
Other
Arm Description
NBUVB
Intervention Type
Radiation
Intervention Name(s)
Narrow band ultraviolet B
Intervention Description
48 sessions of narrow band ultraviolet
Primary Outcome Measure Information:
Title
Effect of NB-UVB on tissue level of IL 15 and IL15Rα in active vitiligo
Description
Change of tissue level of Il-15 and IL-15Rα after 48 session of NB-UVB
Time Frame
4 month
Secondary Outcome Measure Information:
Title
Effect of activity of vitiligo on tissue level of Il-15 and IL-15Rα
Description
Correlation between tissue level of Il-15 and IL-15Rα before and after NB-UVB with activity score (vitiligo digns of activity score from 0 to 15)
Time Frame
4 months
Title
Effect of extent of vitiligo on tissue level of Il-15 and IL-15Rα
Description
Correlation between tissue level of Il-15 and IL-15Rα before and after NB-UVB with extent score (Vitiligo extent plus score )
Time Frame
4 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Age: ≥ 18 years. Both genders. Type of Vitiligo: non segmental vitiligo (NSV). Active disease for less than 6 months (VIDA ≥ +2). No systemic or topical treatment for vitiligo for at least one month. Exclusion criteria: Patients less than 18 years. VIDA ≤ +1. Contraindications to phototherapy (precancerous conditions like Xeroderma pigmentosum , photosensitivity, history of arsenic intake, ionizing radiation, extensive previous exposure to PUVA, patients with a history of melanoma, atypical nevi, non-melanoma skin cancers and patients taking immunosuppressive medications ( Menter et al., 2010 and Mehta & Lim, 2016). Pregnancy and lactation . Patients who received systemic or topical treatment for the past month. patients having any autoimmune diseases .
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nourhan Emad
Organizational Affiliation
Faculty of medicine kasr Elainy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nourhan Emad
City
Cairo
State/Province
Helwan
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
I will share the deidentified data sheet of the results of the trial
IPD Sharing Time Frame
Beginning 3 month and ending 12 month after article publication
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal will be allowed to access the data to achieve aims in the approved proposal Proposal should be directed to nourhanemad693@gmail.com to gain access

Learn more about this trial

Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.

We'll reach out to this number within 24 hrs